|
Novartis discontinues clinical trial of Tasigna®
|
13 April 2011 |
|
Novartis sells global rights to Elidel®, a medicine to treat atopic dermatitis
|
08 April 2011 |
|
Novartis completes acquisition of majority stake in Zhejiang Tianyuan expanding vaccines presence in China
|
24 March 2011 |
|
Novartis receives European Commission approval for Gilenya®
|
21 March 2011 |
|
Novartis committed to provide equivalent of more than USD 3 million in relief aid to Japan earthquake victims
|
17 March 2011 |
|
Novartis gains positive CHMP opinion for Rasilamlo(TM)
|
21 February 2011 |
|
Novartis drug Afinitor® extends progression-free survival in patients with advanced pancreatic NET
|
09 February 2011 |
|
Innovation drives Novartis to double-digit growth for 2010
|
30 January 2011 |
|
Sandoz announces phase II clinical trial for biosimilar version of rituximab
|
13 January 2011 |
|
European Commission approves Tasigna® for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia
|
02 January 2011 |